In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.
You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
-
CORPORATE - 19-01-2016
Kedrion Biopharma strengthens its position on the US market
Granted exclusive rights to commercialize a lifesaving drug in the US
read more -
CORPORATE - 18-01-2016
A brand new location for KEDPlasma donors in the very center of Fürth
Plasma collected is turned into life-saving therapies to serve patients in Germany and worldwide
read more -
CORPORATE - 08-01-2016
KEDPlasma acquires two plasma centers from ImmunoTek LLC in the US
The acquisition is part of a five-year growth plan of supplying highest-quality plasma to Kedrion Biopharma
read more -
CORPORATE - 07-01-2016
Human rabies Ig meets primary endpoint in U.S. pivotal phase 2/3 clinical trial
Strategic agreement between Kedrion and Kamada for its clinical development and marketing
read more
Pages
For more information please contact: pressoffice@kedrion.com
Where 